Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Yanbing Zhou, PhD
Merck
Poster(s):
(P-1074)
Clinical Outcomes in Patients Hospitalized with Exacerbation of Chronic Respiratory Infections treated with Ceftolozane/Tazobactam: Results from SPECTRA
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1075) Treatment Patterns among
Hospitalized Patients with Gram-Negative Infection Treated with Imipenem/Cilastatin/Relebactam (I/R): Retrospective US-based EHR Medical Chart Review
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1076) Describing the clinical characteristics, treatment patterns, and outcomes in hospitalized pneumonia patients treated with Ceftolozane/Tazobactam (C/T): Insights from the SPECTRA Study
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1077) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam (C/T) Real-world Analysis (SPECTRA): Clinical Outcomes and Treatment Patterns from Mexico
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1105) Effectiveness of Imipenem-Relebactam for Multidrug-resistant
Pseudomonas aeruginosa
in Pneumonia and Bloodstream Infections in the United States (MIRAGE)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1113) Treatment Patterns and Clinical Outcomes in Hospitalized Patients with Febrile Neutropenia treated with Ceftolozane/Tazobactam: A Subgroup Analysis of the SPECTRA study
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1537) Comparative effectiveness of early treatment with ceftolozane/tazobactam (C/T) relative to polymyxin (PB)-based therapy for non-COVID-19 patients (pts) with pneumonia (PNA) due to multi-drug resistant
Pseudomonas
aeruginosa
(MDR-PSA) across US Hospitals
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT